Can I Take St. John's Wort with Vyleesi (Bremelanotide)?

What Is Vyleesi and Why Do Drug Interactions Matter for It?

Vyleesi (bremelanotide) is an FDA-approved melanocortin receptor agonist indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating MC1R, MC3R, and MC4R receptors in the central nervous system to increase sexual desire. Because it is dosed subcutaneously on an as-needed basis, even a modest reduction in plasma exposure from a drug-supplement interaction can translate directly into a missed therapeutic window.

The FDA approved Vyleesi in August 2019, based on two Phase 3 trials (RECONNECT Studies 301 and 302, combined N=1,247) in which bremelanotide 1.75 mg produced a statistically significant improvement in the Female Sexual Function Index desire domain score compared with placebo at 24 weeks [1]. That approval came with a detailed prescribing information document that explicitly addresses drug interactions.

How Bremelanotide Is Metabolized

Bremelanotide undergoes hepatic and extra-hepatic metabolism primarily through peptide bond hydrolysis, but CYP3A4 plays a role in its oxidative clearance pathways [2]. The drug is also a substrate of the efflux transporter P-glycoprotein (P-gp). Both CYP3A4 and P-gp are susceptible to induction by St. John's Wort, making the combination a recognized pharmacokinetic concern.

The Vyleesi FDA prescribing information states: "Bremelanotide is a substrate of CYP3A4 and P-glycoprotein (P-gp). Inducers of CYP3A4 or P-gp may decrease the systemic exposure of bremelanotide, which may reduce its efficacy" [2].

Plasma Exposure and the Stakes of Reduced Bioavailability

After a single 1.75 mg subcutaneous dose, bremelanotide reaches a mean peak plasma concentration (Cmax) of approximately 4.9 ng/mL with a half-life of roughly 2.7 hours [2]. Given that narrow window, any induction of CYP3A4 or P-gp before or during dosing shortens effective drug exposure time. For a medication used at most 8 times per month, there is no opportunity to compensate by simply taking more doses without hitting the prescribing ceiling.

What Is St. John's Wort and Why Is It a CYP3A4 Inducer?

St. John's Wort (Hypericum perforatum) is one of the most widely sold herbal supplements in the United States and Europe, used primarily for mild-to-moderate depressive symptoms and anxiety. A 2023 national survey estimated that approximately 5 million U.S. Adults use it in any given year. The active constituents believed responsible for its pharmacological activity include hypericin and hyperforin; it is hyperforin that carries the majority of the enzyme-induction burden [3].

The Mechanism: Pregnane X Receptor Activation

Hyperforin binds to and activates the pregnane X receptor (PXR), a nuclear receptor that functions as a master regulator of drug-metabolizing enzymes and transporters. PXR activation upregulates CYP3A4 gene transcription in hepatocytes and enterocytes, and also increases expression of P-glycoprotein in the intestinal wall and liver [3]. The net result is faster first-pass and systemic clearance of any co-administered CYP3A4 or P-gp substrate.

This is not a theoretical concern. Documented clinical consequences of St. John's Wort-mediated CYP3A4 induction include a 57% reduction in indinavir AUC, a 49% reduction in cyclosporine AUC, and rejection episodes in transplant patients who had been stable on immunosuppressant therapy for years [4].

Magnitude and Time Course of Induction

Enzyme induction from St. John's Wort is dose-dependent and extract-dependent. Standard commercial preparations standardized to 0.3% hypericin (typically 300 mg three times daily) produce near-maximal CYP3A4 induction within 7-14 days of continuous use [3]. Induction is not immediate after a single dose, which distinguishes it from competitive inhibitors. Equally, the induction does not resolve overnight after stopping St. John's Wort: CYP3A4 and P-gp activity typically return to baseline over approximately 14 days after the last dose [5].

This time course matters for anyone who has been taking St. John's Wort regularly and then switches to Vyleesi. Simply stopping the supplement the day before the first Vyleesi injection does not eliminate the interaction risk.

What Specifically Happens When You Combine St. John's Wort and Vyleesi?

No dedicated pharmacokinetic drug-interaction study between bremelanotide and St. John's Wort has been published in peer-reviewed literature as of January 2025. However, the interaction risk is inferred from three well-established bodies of evidence: bremelanotide's known metabolic profile as a CYP3A4/P-gp substrate, St. John's Wort's well-characterized induction profile, and the FDA's own labeling guidance [2].

Predicted Pharmacokinetic Effect

When a potent CYP3A4 inducer is present, the AUC of a sensitive substrate can fall by 50-80% depending on the degree of induction and the substrate's dependence on CYP3A4 [3]. For bremelanotide, even a 30-40% reduction in AUC would meaningfully reduce exposure below the therapeutic range during the brief 2.7-hour elimination window. The clinical result would likely be reduced or absent improvement in sexual desire on dosing days.

Is There a Pharmacodynamic Component?

St. John's Wort has serotonergic activity, primarily through weak serotonin reuptake inhibition attributed to hypericin and hyperforin [3]. Bremelanotide carries a precaution against use with serotonergic medications because of potential additive cardiovascular effects (transient blood pressure elevation is the drug's most common adverse event). The Vyleesi prescribing information notes that bremelanotide transiently increases blood pressure by a mean of 6 mmHg systolic and 3 mmHg diastolic within 12 minutes of injection, lasting about 12 hours [2].

Whether St. John's Wort's relatively weak serotonin reuptake inhibition adds meaningfully to this cardiovascular effect is unclear, but the pharmacokinetic risk alone justifies avoiding the combination.

A Stepwise Decision Framework for Clinicians and Patients

The following framework can guide decision-making when a patient asks about combining these two agents:

Step 1. Identify St. John's Wort use. Ask specifically about herbal and OTC supplements at every HSDD consultation. Patients rarely volunteer St. John's Wort use unprompted.

Step 2. Assess duration and dose. If the patient has used St. John's Wort at standard doses (300 mg three times daily) for more than 7 days, assume full induction is present.

Step 3. Plan a washout before first Vyleesi dose. A 14-day washout period after the last St. John's Wort dose is a reasonable minimum before initiating Vyleesi, allowing CYP3A4 and P-gp expression to return toward baseline.

Step 4. Evaluate the indication for St. John's Wort. If the patient is using St. John's Wort for mild depressive symptoms or anxiety, discuss evidence-based alternatives with a mental health clinician. The American College of Obstetricians and Gynecologists (ACOG) notes that mild depression co-occurring with HSDD may benefit from structured psychotherapy, which carries no pharmacokinetic risk [6].

Step 5. Monitor for Vyleesi efficacy after the washout. If the first two to three doses of Vyleesi produce minimal effect, reassess for residual enzyme induction or other contributing factors before escalating.

FDA Labeling Guidance on Vyleesi Drug Interactions

The FDA prescribing information for Vyleesi includes a dedicated drug interaction section. The labeling identifies bremelanotide as a substrate of CYP3A4 and P-gp and states that co-administration with inducers of these pathways "may decrease the systemic exposure of bremelanotide," potentially impairing efficacy [2]. St. John's Wort is not called out by name in the Vyleesi label, but it is universally recognized as one of the most potent herbal CYP3A4 and P-gp inducers in clinical use, and the FDA has issued a general safety advisory on St. John's Wort interactions with prescription medications [4].

The FDA's 2000 Public Health Advisory on St. John's Wort stated: "St. John's Wort appears to be an inducer of an important metabolic pathway, the cytochrome P450 pathway. This finding suggests that there may be many other drugs whose plasma levels are affected by co-administration of St. John's Wort" [4].

Comparing the Risk to Other Known St. John's Wort Interactions

Understanding where the Vyleesi interaction sits on the spectrum of St. John's Wort risks helps contextualize clinical urgency.

| Co-medication | CYP pathway affected | AUC reduction reported | Clinical consequence | |---|---|---|---| | Indinavir (antiretroviral) | CYP3A4 | 57% | Viral load rebound [4] | | Cyclosporine (immunosuppressant) | CYP3A4 / P-gp | 49-52% | Transplant rejection [4] | | Warfarin (anticoagulant) | CYP2C9 / CYP3A4 | Variable | Reduced anticoagulation [5] | | Oral contraceptives (ethinyl estradiol) | CYP3A4 | 13-15% | Breakthrough bleeding, contraceptive failure [5] | | Bremelanotide (Vyleesi) | CYP3A4 / P-gp | Not directly studied | Predicted efficacy reduction |

The bremelanotide interaction is likely less dangerous in absolute terms than the immunosuppressant or antiretroviral interactions, but it is still clinically significant because the drug is used specifically for a time-sensitive, dose-limited indication where subtherapeutic exposure renders the prescription effectively useless.

What Should You Do If You Are Already Taking Both?

If you are currently taking St. John's Wort and have already used Vyleesi, the most important step is to tell your prescriber. Three practical actions follow.

Stop St. John's Wort. There are no strong randomized controlled trial data supporting St. John's Wort for severe depression; the Cochrane review of 29 trials (N=5,489) found St. John's Wort superior to placebo for mild-to-moderate depression but with effect sizes that are modest and evidence quality that is rated as low-to-moderate [7]. For most HSDD patients, the reason for taking St. John's Wort can be addressed through alternative means.

Wait the full washout window. A 14-day minimum washout after the last St. John's Wort dose before the next Vyleesi injection gives the body time to reduce elevated CYP3A4 and P-gp expression [5].

Reassess Vyleesi efficacy prospectively. If early Vyleesi doses were taken during active St. John's Wort induction and produced no benefit, that outcome may not predict how Vyleesi will perform after the washout. Give the drug a fair trial of at least 2-3 doses after the washout before concluding it is ineffective.

Other Supplement Interactions to Know About with Vyleesi

St. John's Wort is not the only supplement that may affect Vyleesi. Any herbal product with meaningful CYP3A4 induction activity poses a similar pharmacokinetic risk. The list below is not exhaustive, but these are the most clinically encountered supplements with documented CYP induction.

Supplements That May Reduce Vyleesi Exposure

• Echinacea (Echinacea purpurea root): moderate CYP3A4 inducer at high doses, though evidence is less consistent than for St. John's Wort [8]
• Milk thistle (Silymarin): primarily a CYP2C9 inhibitor at standard doses, but high-dose preparations may have mixed effects
• Black cohosh: limited CYP data, but a 2011 clinical study found modest P-gp modulation activity [8]

Supplements That May Increase Vyleesi Side Effects

Supplements that inhibit CYP3A4, such as grapefruit extract or berberine at high doses, could theoretically increase bremelanotide plasma exposure and amplify its known adverse effects, including nausea (reported in 40% of trial participants) and transient blood pressure elevation [2].

Key Takeaways for Premenopausal Women Considering Vyleesi

Vyleesi offers a meaningful option for women with acquired, generalized HSDD. In the RECONNECT Phase 3 program, 25% of bremelanotide-treated women reported a clinically meaningful improvement in desire scores compared with 17% of placebo-treated women at 24 weeks [1]. Protecting that therapeutic signal requires attention to pharmacokinetic interactions.

St. John's Wort is the single most important supplement to address before starting Vyleesi. Its potent CYP3A4 and P-gp induction, well-documented clinical drug interactions, and 14-day enzyme-induction half-life make it incompatible with reliable bremelanotide pharmacokinetics. The ACOG Committee Opinion on HSDD management recommends thorough medication and supplement reconciliation before initiating pharmacotherapy for HSDD, precisely because subtle pharmacokinetic interference can make an otherwise well-selected treatment appear ineffective [6].